The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity
Open Access
- 1 February 2009
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 11 (1) , 22-32
Abstract
First-line therapy for patients with glioblastoma multiforme includes treatment with radiation and temozolomide (TMZ), an oral DNA alkylating chemotherapy. Sensitivity of glioma cells to TMZ is dependent on the level of cellular O(6)-methylguanine-DNA methyltransferase (MGMT) repair activity. Several common coding-region polymorphisms in the MGMT gene (L84F and the linked pair I143V/K178R) modify functional characteristics of MGMT and cancer risk. To determine whether these polymorphic changes influence the ability of MGMT to protect glioma cells from TMZ, we stably overexpressed enhanced green fluorescent protein (eGFP)-tagged MGMT constructs in U87MG glioma cells. We confirmed that the wild-type (WT) eGFP-MGMT protein is properly localized within the nucleus and found that L84F, I143V/K178R, and L84F/I143V/K178R eGFP-MGMT variants exhibited nuclear localization patterns indistinguishable from WT. Using MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] proliferation and clonogenic survival assays, we confirmed that WT cells expressing eGFP-MGMT are resistant to TMZ treatment compared with control U87MG cells, and that each of the polymorphic eGFP-MGMT variants confers similar resistance to TMZ. However, upon exposure to O(6)-benzylguanine (O(6)-BG), a synthetic MGMT inhibitor, the L84F and L84F/I143V/K178R variants were degraded more rapidly than WT or I143V/K178R in a proteasome-dependent manner. Despite the increased O(6)-BG- stimulated protein turnover caused by the L84F alteration, cells expressing L84F eGFP-MGMT did not exhibit altered sensitivity to the combination of O(6)-BG and TMZ compared with WT cells. In conclusion, we demonstrated that the L84F polymorphic variant has altered protein turnover without modifying sensitivity of U87MG cells to TMZ or combined TMZ and O(6)-BG. These findings may provide a clue to determining the clinical significance of MGMT coding-region polymorphisms.Keywords
This publication has 32 references indexed in Scilit:
- Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferaseBiochemical Pharmacology, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Induction of the DNA repair gene O6-methylguanine—DNA methyltransferase by dexamethasone in glioblastomasJournal of Neurosurgery, 2004
- Nuclear-localizing O6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection markerExperimental Hematology, 2004
- A genotype of the polymorphic DNA repair gene MGMT is associated withde novoglioblastomaNeurological Research, 2003
- O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanomaBritish Journal of Cancer, 2003
- Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cellsCancer Chemotherapy and Pharmacology, 2003
- Inactivation and degradation of O(6)-alkylguanine-DNA alkyltransferase after reaction with nitric oxide.2002
- The Modified Human DNA Repair EnzymeO6-Methylguanine-DNA Methyltransferase Is a Negative Regulator of Estrogen Receptor-Mediated Transcription upon Alkylation DNA DamageMolecular and Cellular Biology, 2001
- Ubiquitination-Dependent Proteolysis of O6-Methylguanine-DNA Methyltransferase in Human and Murine Tumor Cells following Inactivation with O6-Benzylguanine or 1,3-Bis(2-chloroethyl)-1-nitrosoureaBiochemistry, 1996